The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Antiviral therapy for HCV recurrence after liver transplantation is a challenging issue. How do we manage treatment?

Antiviral Treatment for HCV Recurrence After Liver Transplantation When, How Much and for How Long?

XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and ...

In other recent news, AbbVie has received FDA approval for MAVYRET as the first oral treatment for acute hepatitis C, expanding its use to include adults and children aged three and older. The ...

AbbVie reports favorable Phase 3 results for migraine therapy Atogepant Biotech expansion strategy includes migraine, oncology, and liver disease treatments Dividend-paying stock remains steady amid ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

In other recent news, AbbVie received FDA approval for MAVYRET, now the first oral treatment for acute hepatitis C, expanding its use to both adults and children. This approval follows a Phase 3 study ...